Shijiazhuang Yiling Pharmaceutical (SHE:002603) said its Tongluo Mingmu capsules were included in the national medical insurance catalog.
Tongluo Mingmu is used for treating limited to simple type two diabetic retinopathy, according to a Friday filing with the Shenzhen bourse.
The inclusion is valid until Dec. 31, 2026.